Chemotherapy News and Research

Latest Chemotherapy News and Research

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis’ lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.

10 Feb 2010

Phase III BSD-2000 Hyperthermia System-chemotherapy combination study for pancreatic cancer initiated

BSD Medical Corporation reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System in combination with chemotherapy for the treatment of pancreatic cancer patients after R0/R1 surgical resection of their tumor (complete removal or only microscopic tumor remaining).

9 Feb 2010

Biogen Idec reports 2009 fourth quarter and full year earnings

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.

9 Feb 2010

Picis introduces LYNX C/Point revenue management solution for chemotherapy clinics

Picis today announced the immediate availability of an enhancement to its Picis LYNX C/Point® revenue management solution designed specifically for hospital-owned chemotherapy clinics.

9 Feb 2010

Genta commences Phase 2 trial of tesetaxel on first subject

Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company’s newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta’s experience in melanoma clinical research.

9 Feb 2010

MCGHealth Children's Medical Center installs new playground to promote physical and occupational therapy

PLAYTIME LLC is pleased to announce the installation of a new, colorful dinosaur-themed indoor playground at MCGHealth Children's Medical Center in Augusta, GA.

8 Feb 2010

Over 12,000 courses of lung cancer treatment completed with Accuray's CyberKnife radiosurgery

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that more than 12,000 courses of lung cancer treatment have been completed with CyberKnife radiosurgery. Usage of CyberKnife radiosurgery for lung cancer continues to grow, as illustrated by a 25 percent increase year over year in calendar year 2009.

6 Feb 2010

Strativa Pharmaceuticals' Zuplenz NDA: FDA issues complete response letter

Strativa Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the new drug application (NDA) for Zuplenz® (ondansetron) oral soluble film for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery.

6 Feb 2010

EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award

Gentium S.p.A. today announced that the abstract titled, "Defibrotide prevents hepatic VOD and reduces significantly VOD-associated complications in children at high risk: final results of a prospective phase II/III multicentre study," has been awarded the Van Bekkum Award for the best abstract submitted to the physician's program for the European Group for Blood and Marrow Transplantation's (EBMT) 36th Annual Meeting, to be held in Vienna, March 21-24, 2010.

5 Feb 2010

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

A comprehensive study of the components of the delivery of modern-day cancer care in community oncology practices revealed that Medicare covers only 56% of the actual costs of administering chemotherapy and providing related infusion room services to seniors with cancer. The remaining costs -- for essential services provided such as treatment planning, care coordination, and follow-up care planning -- are not reimbursed by Medicare, causing many oncology practices to struggle to continue to provide care under the Medicare program.

5 Feb 2010

Oxford Finance Corporation announces $25M credit facility to EUSA Pharma

Oxford Finance Corporation today announced that it is the agent and primary lender for a $25 million credit facility provided to EUSA Pharma. MidCap Financial and Silicon Valley Bank are co-lenders in the transaction.

5 Feb 2010

ARUP Laboratories adds three downstream cost calculators to its Suite of Utilization Management Services

ARUP Laboratories announced the release of three groundbreaking tools, downstream cost calculators, to its Suite of Utilization Management Services.

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Wolters Kluwer Health relaunches flagship drug information reference as Facts & Comparisons eAnswers

Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that it has relaunched its flagship drug information reference as Facts & Comparisons® eAnswers.

4 Feb 2010

ASTRO leads the way to help physicians improve safety and reduce medical errors

The American Society for Radiation Oncology has committed to a six-point patient protection plan that will improve safety and quality and reduce the chances of medical errors, ASTRO Board Chairman Tim R. Williams, M.D., said today.

4 Feb 2010

Cancer Research UK opens Cambridge Cancer Centre

The launch of a centre today (Wednesday) puts Cambridge at the forefront of cancer research, bringing benefits to patients in the South East.

4 Feb 2010

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.

4 Feb 2010

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in patients with refractory metastatic colorectal cancer.

3 Feb 2010

News article on the evolving role of hyperthermia in cancer therapy

BSD Medical Corp. reports publication of a news article by the Journal of the National Cancer Institute on the evolving role of hyperthermia in cancer therapy titled, “International Study of Hyperthermia Spurs Hope in U.S.” (J. Natl. Cancer Inst. 2010 102: 79-81; doi:10.1093/jnci/djp530).

3 Feb 2010

Dayton Physicians select IntrinsiQ’s chemotherapy management system for improving patient care

Dayton Physicians LLC, one of Ohio’s leading multi-specialty cancer treatment centers, has selected IntrinsiQ’s IntelliDose® clinical software to manage complex chemotherapy treatment, safely and efficiently.

3 Feb 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Phase III BSD-2000 Hyperthermia System-chemotherapy combination study for pancreatic cancer initiated

Biogen Idec reports 2009 fourth quarter and full year earnings

Picis introduces LYNX C/Point revenue management solution for chemotherapy clinics

Genta commences Phase 2 trial of tesetaxel on first subject

MCGHealth Children's Medical Center installs new playground to promote physical and occupational therapy

Over 12,000 courses of lung cancer treatment completed with Accuray's CyberKnife radiosurgery

Strativa Pharmaceuticals' Zuplenz NDA: FDA issues complete response letter

EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award

Nearly 50% of essential services provided for cancer treatment not reimbursed by Medicare

Oxford Finance Corporation announces $25M credit facility to EUSA Pharma

ARUP Laboratories adds three downstream cost calculators to its Suite of Utilization Management Services

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Wolters Kluwer Health relaunches flagship drug information reference as Facts & Comparisons eAnswers

ASTRO leads the way to help physicians improve safety and reduce medical errors

Cancer Research UK opens Cambridge Cancer Centre

Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

News article on the evolving role of hyperthermia in cancer therapy

Dayton Physicians select IntrinsiQ’s chemotherapy management system for improving patient care

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in